Canaccord initiated coverage of Heartflow (HTFL) with a Buy rating and $35 price target The firm believes the company’s artificial intelligence-based products are positioned to change the standard of care in the detection of coronary artery disease. Heartflow has “compelling” clinical and economic data, which is beginning to be reflected in society guidelines and reimbursement in the U.S., the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HTFL:
- Heartflow initiated with a Buy at Stifel
- Heartflow initiated with an Overweight at JPMorgan
- Heartflow initiated with an Overweight at Piper Sandler
- HeartFlow, Inc.: Innovative Technology and Strong Financial Performance Drive Buy Rating
- HeartFlow, Inc.: Positioned for Growth in AI-Powered Coronary Diagnostics with Strong Market Potential